Journal of Antimicrobial Chemotherapy Publishes Paper on Kane Biotech’s PS/CHX Coating for Medical Devices

Kane Biotech Inc. (TSX VENTURE: KNE) –

A biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce a research publication on its PS/CHX technology. PS/CHX, one of the Company’s lead antimicrobial compositions, is a patent pending combination of Chlorhexidine and Protamine Sulfate. The paper appeared in the recent online edition of the Journal of Antimicrobial Chemotherapy (doi:10.1093/jac/dkn006; Impact Factor: 3.9).

The publication, entitled “Efficacy of Combination of Chlorhexidine and Protamine Sulphate against Device-Associated Pathogens” authored by Dr. Rabih Darouiche (Darouiche et al.) at Baylor College of Medicine, Houston, Texas, demonstrates that the combination of protamine sulfate and chlorhexidine (PS/CHX) has a synergistic inhibitory effect on E. coli and synergistic antibiofilm activity against E. coli, Pseudomonas aeruginosa and Staphylococcus epidermidis.

“The combination was notably synergistic against E. coli, a very common uropathogen, and showed in vitro inhibitory effect on all of the nine tested catheter-associated pathogens” stated Dr. Darouiche. “This study demonstrated that the combination provides strong synergistic antimicrobial and antibiofilm activity against uropathogens. More importantly, the combination-coated urinary catheter showed robust in vivo protection against E. coli colonization and infection in a rabbit model”.

“This publication further demonstrates the strength of our technology and its potential application in preventing hospital acquired infections” explained Mr. Gord Froehlich, president and CEO of Kane. “The data is also a strong indication that PS/CHX has broad applications that reach beyond coating medical devices and we are now exploring new applications in the global anti-infective market.”

Kane Biotech is partnered with Harland Medical Systems for the commercialization of this lead technology for coating urinary, venous access and veterinary catheters. This product, as demonstrated in the publication, has the potential to reduce the occurrence of catheter-related infections, a growing problem that costs the U.S. healthcare system billions of dollars annually. Catheter associated urinary tract infections account for 40% of all hospital-acquired infections and catheter-related bloodstream infections associated with the use of central venous catheters are a major source of morbidity and mortality in the U.S.

About Dr. Darouiche

Rabih O. Darouiche, M.D., is the founder and director of the Center for Prostheses Infection. He is a VA Distinguished Service Professor in the Departments of Medicine and Physical Medicine & Rehabilitation at Baylor College of Medicine, and a staff physician in the Medical (Infectious Disease Section) and Spinal Cord Injury Services at the Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas. Board Certified in internal medicine, infectious disease, and spinal cord injury medicine. Dr. Darouiche is an outstanding clinician and excellent academician. Additionally, Dr. Darouiche is an internationally renowned researcher with clinically proven approaches for rendering medical devices anti-infective.

The author of over 130 articles and textbook chapters, Dr. Darouiche is known for his prominent work in the area of prosthesis infection. His publications, such as the lead article in the New England Journal of Medicine (1999; 340:1-8) entitled, “A Comparison of Two Antimicrobial-Impregnated Central Venous Catheters,” have had an overwhelming impact on patient care.

About Baylor College

Baylor College of Medicine (BCM) in Houston, Texas was founded in 1900 and is today an internationally respected medical and research institution known for excellence in education, research and patient care.

For 2008, U.S. News & World Report again has ranked the college 10th overall among the nation’s top medical schools for research and 11th for primary care. BCM is also listed 13th among all U.S. medical schools for National Institutes of Health funding, and No. 1 for research expenditures in biological science by the National Science Foundation.

Located in the Texas Medical Center, a 700-acre complex housing 42 member institutions, BCM has affiliations with seven teaching hospitals, each with a national and international reputation for medical excellence.

The college has total research support of $374 million, with $314 million from federal sources, and more than 90 research and patient-care centers and units. Currently, BCM trains more than 3,000 medical, graduate, nurse anesthesia, and physician assistant students, as well as residents and post-doctoral fellows.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and approximately 80% of all human bacterial infections involve biofilms. The healing of chronic wounds alone costs the Unites States health care system $20 Billion per year.

Kane Biotech is currently developing two lead technology platforms:

– DispersinB(TM), a novel antibiofilm enzyme that inhibits as well as disperses microbial biofilms, with applications in wound care, medical devices, oral care and animal healthcare. Kane is currently developing a DispersinB(TM) based antibiofilm/antimicrobial wound gel for healing chronic wounds.

– PS/CHX, a broad-spectrum antimicrobial/antibiofilm composition comprising FDA-approved protamine sulfate and chlorhexidine, with applications in anti-infective medical device coatings, animal care and dairy and food processing industries. This technology has been licensed to Harland Medical Systems to develop antimicrobial urinary and venous access catheters.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, “forward-looking statements”). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as “believe,”"anticipate,”"expect,”"intend,”"plan,”"will,”"may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane’s early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers’ willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane’s filings with Canadian securities regulatory authorities, as well as Kane’s ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane’s forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

 Contacts: Kane Biotech Inc. Justin Gagnon Manager, Investor Relations (204) 478-5602 (204) 453-1314 (FAX) Email: jgagnon@kanebiotech.com Website: www.kanebiotech.com

SOURCE: Kane Biotech Inc.